Sign In
Buy BHVN
$13.57
-0.0500 (-0.367%)
At Close: Jun 18, 2026
Biohaven: Upgrading To Buy On Protein Degraders Pivotal Study Initiations
03:28pm, Thursday, 18'th Jun 2026
Biohaven (BHVN) is upgraded from "Hold" to "Buy," driven by FDA regulatory shifts and strong biomarker data for its protein degrader pipeline. The company is set to initiate pivotal studies for BHV-13
Biohaven Reports First-in-Human Dosing of Oral PKM2 Modulator, BHV-8100, Targeting Metabolic Restoration and Immunomodulation
07:30am, Monday, 01'st Jun 2026
BHV-8100 is an orally administered, brain-penetrant PKM2 modulator; a novel therapeutic class addressing the bioenergetic and immunometabolic basis of systemic and central nervous system disorders Fir
Biohaven: Despite Today's Gains, I Remain Skeptical
03:12pm, Wednesday, 27'th May 2026
Biohaven Ltd. shared an R&D presentation today in relation to its epilepsy asset and also updated on its degrader programs. BHVN - spun out of the original Biohaven after its acquisition by Pfizer - a
BHV-1300 demonstrated deep, rapid, and sustained lowering of pathogenic TSHR autoantibodies (TSHR-IgG1) in patients with Graves' hyperthyroidism receiving 1000 mg SC weekly, with mean reductions in TS
In a randomized, placebo-controlled, time-to-event trial in idiopathic generalized epilepsy (IGE), the median time to the second day with a generalized tonic-clonic seizure was 141 days in the opakali
Biohaven Ltd. (BHVN) Upgraded to Buy: Here's Why
01:01pm, Tuesday, 05'th May 2026
Biohaven Ltd. (BHVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results
04:02pm, Monday, 04'th May 2026
Biohaven to update clinical, regulatory, and operational progress at annual R&D Day at the upcoming Yale Innovation Summit on May 27, 2026. Advancement of high-value, late-stage priority programs: Piv
Biohaven: Downgrade To Hold On Troriluzole Setback And Obesity Data 2nd Half 2026
04:07pm, Wednesday, 15'th Apr 2026
Biohaven Ltd. is downgraded from Strong Buy to Hold following the FDA's Complete Response Letter for troriluzole in Spinocerebellar Ataxia. BHVN pivots focus to three late-stage programs: MODE/TRAP de
Why Biohaven Stock Crushed it on Monday
05:41pm, Monday, 13'th Apr 2026
That pundit flagged the stock as a buy. He also expects it to more than double in price.
Aberdeen Group plc Buys Shares of 693,452 Biohaven Ltd. $BHVN
03:37am, Thursday, 09'th Apr 2026
Aberdeen Group plc bought a new stake in Biohaven Ltd. (NYSE: BHVN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The f
SG Americas Securities LLC Grows Holdings in Biohaven Ltd. $BHVN
04:47am, Wednesday, 08'th Apr 2026
SG Americas Securities LLC grew its holdings in shares of Biohaven Ltd. (NYSE: BHVN) by 291.8% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential
01:17pm, Monday, 23'rd Mar 2026
Sarissa Capital Management added 513,184 shares in Biohaven during the fourth quarter. The quarter-end position value increased by $5.79 million as a result of the transaction.
Biohaven Ltd. (NYSE:BHVN) Given Average Recommendation of “Moderate Buy” by Brokerages
02:31am, Sunday, 22'nd Mar 2026
Biohaven Ltd. (NYSE: BHVN - Get Free Report) has earned an average recommendation of "Moderate Buy" from the seventeen brokerages that are covering the stock, MarketBeat.com reports. One equities rese
This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash
07:49pm, Saturday, 21'st Mar 2026
DAFNA Capital Management bought 720,000 shares of Biohaven in the fourth quarter; the estimated trade size was $8.92 million, based on average prices in the fourth quarter of 2025. Meanwhile, the quar
Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
07:30am, Thursday, 19'th Mar 2026
Phase 2 study in obesity, evaluating treatment with once-weekly and once-monthly taldefgrobep alfa as monotherapy, is now fully enrolled; topline data expected in 2H 2026. Taldefgrobep is a novel inhi
